Centre de recherche de l'Hôpital Maisonneuve-Rosemont (CR-HMR)

What Centre de recherche de l'Hôpital Maisonneuve-Rosemont (CR-HMR) does

Centre de recherche de l'Hôpital Maisonneuve-Rosemont (CR-HMR) is a public healthcare research institute located in Montreal, Quebec, operating as the research arm of Hôpital Maisonneuve-Rosemont within CIUSSS de l'Est-de-l'Île-de-Montréal and formally affiliated with Université de Montréal. The institute is organized around three principal research axes — Immunology-Oncology, Nephrology, and Vision Health — and conducts basic, translational, and clinical research with an annual operating footprint of roughly 726 active projects and approximately 125 scientific publications per year. Its staff comprises 41 researchers, 134 students, and 114 research professionals, supported by 10 Canada Research Chairs and embedded within two designated Centres of Excellence: C3i (Centre de commercialisation en immunothérapie du cancer) and CellCan.

CR-HMR operates specialized technical platforms spanning cellular and molecular therapy, regenerative medicine, biophotonics, and optical coherence tomography (OCT). These platforms underpin both internal research and externally sponsored programs, including the $27.9M Quebec Cancer Consortium initiative (2019) and a portfolio of federally and provincially funded grants. Outputs include peer-reviewed publications, clinical trial activity, training of graduate and postdoctoral trainees, and commercialization pathways managed through C3i.

The institute's business model is non-commercial: operating revenue is derived from government research grants (FRQS core funding of $10.6M annually, plus CIHR, CFI, Oncopole, and Quebec Ministry allocations), institutional and philanthropic donations, and sponsored research agreements. CR-HMR serves as a public-sector research provider serving patients within the Quebec health system, clinician-scientist trainees, and downstream commercialization partners in cell therapy and immuno-oncology.

Name

Centre de recherche de l'Hôpital Maisonneuve-Rosemont (CR-HMR)

Legal name

Centre de recherche de l'Hôpital Maisonneuve-Rosemont

Website

https://crhmr.ciusss-estmtl.gouv.qc.ca

Company type

Private

Operating status

Operating

Headcount range

51–100 employees

Short description

CR-HMR is a public healthcare research institute in Montreal, affiliated with Université de Montréal and CIUSSS de l'Est-de-l'Île-de-Montréal, conducting basic, translational, and clinical research in immunology-oncology, nephrology, and vision health, funded by government grants.

Ownership category

akta.pro rank

Product category

Medical Research Services

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industry

Decentralized/Hybrid Trial Enablement (DCT) Platforms (HLACAOAL)

Keywords

• Medical research center
• Clinical research services
• Regenerative medicine research
• Cancer immunotherapy research
• Translational health research

Headquarters

HQ city

Montréal

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations

Revenue model

1. Government research funding: Funding from government granting agencies including FRQS, CIHR, NSERC, SSHRC for scholarships, research chairs, project grants, and equipment acquisition.
2. Philanthropic donations: Support from the Fondation de l'Hôpital Maisonneuve-Rosemont for specific research projects, chairs, scholarships, and equipment.
3. Private sector partnerships: Contributions from private companies, foundations, and not-for-profit organizations for research collaborations.
4. Federal emergency fund (FUCRC): COVID-19 emergency funding for research continuity from the federal government ($450M program, with $1,146,229 received by CIUSSS).

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

The Centre de recherche de l'Hôpital Maisonneuve-Rosemont (CR-HMR) is a university-affiliated hospital research centre that conducts fundamental, translational, clinical, and evaluative research across three primary axes: immunology-oncology, nephrology, and vision health. It operates specialized research units, technical platforms (animal care, flow cytometry, microscopy), research chair programs, and training pipelines producing peer-reviewed publications, clinical therapies, and highly qualified personnel.

Product overview

CR-HMR is a healthcare research institution operating as a single unified research center with multiple specialized research axes and units. The center is organized around three main research axes: Immunology-Oncology (cellular therapy, immunotherapy, cancer research), Nephrology (kidney disease, pharmacoepidemiology), and Vision Health (corneal transplantation, biophotonics, retinal diseases). Supporting these axes are technical platforms (animal care, flow cytometry, microscopy), research chair programs, clinical research across multiple specialties, and specialized research units covering cellular immunogenetics, DNA replication and genome stability, cancer immunology, pharmacoepidemiology, neurovascular eye disease, and biophotonics. The center also hosts training and education programs including scholarships, internships, and seminars. The institution is affiliated with Université de Montréal and is part of two Networks of Centres of Excellence: C3i (Centre d'excellence en commercialisation en immunothérapie du cancer) and CellCan (Réseau de médecine régénératrice et de thérapie cellulaire).

Differentiator

Problem solved

Functional benefit

Brands

• C3i - Centre d'excellence en commercialisation en immunothérapie du cancer: Centre of Excellence for Cancer Immunotherapy Commercialization, part of the Networks of Centres of Excellence
• CellCan - Réseau de médecine régénératrice et de thérapie cellulaire

Products and services

• Immunology-Oncology Research Core research axis focusing on cellular and molecular therapy, immunotherapy, T lymphocyte biology, adoptive immunotherapy, and cancer immunology, serving patients with cancer and immune-related diseases.
• Nephrology Research Core research axis focused on kidney disease including pharmacoepidemiology, dialysis complications, and renal side effects of medications, serving kidney disease patients and clinical nephrologists.
• Vision Health Research Core research axis focused on ocular diseases including corneal transplantation, biophotonics, retinal diseases, age-related macular degeneration, glaucoma, and space-associated neuro-ocular syndrome.
• Evaluative Research and Patient Experience Research axis dedicated to evaluative research, advanced nursing practice, and patient experience, including influence on WHO 2025 State of the World's Nursing report.
• Clinical Research Programs Clinical research across multiple specialties including anesthesia, cardiology, bone marrow transplantation, infectious diseases, multiple myeloma, nephrology, radiation oncology, nursing-oncology, and rheumatology.
• Technical Platforms Shared research infrastructure including animal care facilities, flow cytometry, and microscopy, supporting researchers across all three research axes.
• Research Chair Program Ten research chairs supporting excellence in fields such as corneal transplantation, retinal cell biology, and advanced nursing practice, including the Tier 1 Canada Research Chair in Retinal Cell Biology.

Quantifiable outcome

• 726 ongoing clinical research projects
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Partnerships

Six partnerships are on record, tiered core, flagship and notable.

• Université de MontréalcoreStrategic or Co-development PartnerAcademic affiliation with Université de Montréal. CR-HMR researchers hold faculty positions and students can pursue degrees at UdeM. The centre is recognized by the Fonds de recherche du Québec-Santé as part of this affiliation.
• C3i (Centre d'excellence en commercialisation en immunothérapie du cancer)coreStrategic or Co-development PartnerOne of two Centres of Excellence part of the Networks of Centres of Excellence. Focuses on cancer immunotherapy commercialization.
• CellCan (Réseau de médecine régénératrice et de thérapie cellulaire)coreStrategic or Co-development PartnerOne of two Centres of Excellence part of the Networks of Centres of Excellence. Focuses on regenerative medicine and cell therapy.
• CIUSSS de l'Est-de-l'Île-de-MontréalcoreStrategic or Co-development PartnerCR-HMR is part of the CIUSSS de l'Est-de-l'Île-de-Montréal healthcare network. The centre contributes to the academic mission of the CIUSSS.
• Quebec Cancer Consortium for Novel Therapeutics and BiomarkersflagshipStrategic or Co-development PartnerConsortium including Hôpital Maisonneuve-Rosemont that received $10M from Quebec government plus $17M from partners for a total of $27.9M to double patient recruitment for clinical oncology trials and develop personalized medicine and immunotherapy infrastructure.
• NASAnotableStrategic or Co-development PartnerCollaboration with NASA on space-associated neuro-ocular syndrome (SANS) research using OCT imaging.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Institut de recherches cliniques de Montréal (IRCM): Montreal-based biomedical research institute with similar scope across fundamental and clinical research, university affiliation, and Quebec public funding structure. Comparable size and research mandate.
• CHU Sainte-Justine Research Centre: Mother-child university hospital research centre in Montreal, also part of a Quebec CIUSSS network, with comparable funding profile and university-affiliated hospital research model.
• Research Institute of the McGill University Health Centre (RI-MUHC): Hospital-based research institute in Montreal with multi-axis programs in cancer, nephrology, and vision science. Comparable scope, university affiliation, and Quebec/Canadian public funding model.
• Centre de recherche du CHUM (CRCHUM): University hospital-affiliated research centre in Montreal with comparable axes across cancer, nephrology, and vision research, and similar CIUSSS-style integration. Directly comparable in mission, structure, and Quebec public funding model.
• CHU de Québec-Université Laval Research Centre: Quebec university hospital research centre with comparable axes, CIUSSS-style integration, and FRQS-recognized funding. Direct peer in the Quebec public hospital research ecosystem.
• Ottawa Hospital Research Institute (OHRI): Large Canadian hospital-affiliated research institute with multi-program research portfolio, comparable to CR-HMR in mission and scale. Comparable in clinical research output and grant-funded model.
• Lady Davis Institute (Jewish General Hospital): Hospital-based research institute in Montreal affiliated with McGill University, conducting clinical and fundamental research across multiple specialties. Similar Quebec hospital research centre structure.

Regional players

• Vancouver Coastal Health Research Institute (VCHRI): Western Canadian hospital research institute with comparable multi-axis biomedical research program. Operates in a different geography (British Columbia) but follows similar hospital-affiliated research centre model.
• Alberta Health Services Research: Prairie-region hospital research network with comparable scope across clinical research axes. Different geography but similar Canadian publicly funded hospital research operating model.

Broad incumbents

• University Health Network (UHN) Research: Toronto's largest hospital-affiliated research enterprise with broad multi-specialty research including cancer and vision. Comparable in clinical research breadth, but operates at substantially larger scale and broader portfolio.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks4 records

Key highlights6 records

Customer concentration

• Xfacebook.com/santequebec.estilemontreal
• YouTubeyoutube.com/@santequebec_eimtl
• Facebookfacebook.com/santequebec.estilemontreal
• LinkedInlinkedin.com/company/crhmr
• Instagraminstagram.com/santequebec.eimtl

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Centre de recherche de l'Hôpital Maisonneuve-Rosemont (CR-HMR)